Clinical and economic benefits of lenzilumab plus standard of care compared with standard of care alone for the treatment of hospitalized patients with COVID-19 in the United States from the hospital perspective

Adrian Kilcoynea Humanigen Inc, Burlingame, CA, United StatesCorrespondence[email protected]

Edward Jordana Humanigen Inc, Burlingame, CA, United States

Allen Zhoub EVERSANA, Burlington, ON, Canada

Kimberly Thomasb EVERSANA, Burlington, ON, Canada

Alicia N. Pepperb EVERSANA, Burlington, ON, Canada

Dale Chappella Humanigen Inc, Burlingame, CA, United States

Miyuru Amarapalaa Humanigen Inc, Burlingame, CA, United States

Avery Hughesb EVERSANA, Burlington, ON, Canada

Melissa Thompsonb EVERSANA, Burlington, ON, Canada

show all

Citations (3)

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (1)

Ivo Abraham, Kenneth K. C. Lee & Mike Gregg. (2023) Journal of Medical Economics in review: high impact articles from 2022. Journal of Medical Economics 26:1, pages 303-307.
Read now

Articles from other publishers (2)

Jamie Elvidge, Gareth Hopkin, Nithin Narayanan, David Nicholls & Dalia Dawoud. (2023) Diagnostics and treatments of COVID-19: two-year update to a living systematic review of economic evaluations. Frontiers in Pharmacology 14.
Crossref

Nusrath Yasmeen, Harikrishnan Selvaraj, Sudarshan S Lakhawat, Manali Datta, Pushpender K Sharma, Ajay Jain, Rakhi Khanna, Jayalakshmi Srinivasan & Vikram Kumar. (2023) Possibility of averting cytokine storm in SARS-COV 2 patients using specialized pro-resolving lipid mediators. Biochemical Pharmacology 209, pages 115437.
Crossref

Clinical and economic benefits of lenzilumab plus standard of care compared with standard of care alone for the treatment of hospitalized patients with COVID-19 in the United States from the hospital perspective

Articles from other publishers (2)

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Clinical and economic benefits of lenzilumab plus standard of care compared with standard of care alone for the treatment of hospitalized patients with COVID-19 in the United States from the hospital perspective

Citations (3)

Read on this site (1)

Articles from other publishers (2)

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date